Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab

K. Wang,H. Sun, X. Bai,Z-Y. Huang,T. Song,M. Chen,M. Kuang, B. Xiang, Y. Zeng,L-X. Liu,D. Li,Y. Chen,J. Cai,B. Xing,T. Peng, X. Zhang, X. Zhu, J. Zhou, J. Fan, F. Shen

Annals of Oncology（2023）

Cited 0|Views47

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined